On the contrary, the silencing of PHD2 expression in a mouse osteosarcoma, lung carcinoma, and melanoma has been shown to restrict tumor growth suggesting PHD2 to be a potential target for anti‐tumoral therapy.34, 39. The gene discussed is EGLN1; the disease is neoplasm.